Raynaud’s Phenomenon as a Manifestation of Vasculitis C – ANCA: Case Report and Literature Review
Main Article Content
Abstract
Raynaud's phenomenon is a vasospastic condition affecting capillaries in the distal region of the extremities. It is divided into primary and secondary and 80-90% of patients are associated with primary or idiopathic disease, while 10-20% are secondary, with multiple etiologies including connective tissue, vascular, hematologic, and endocrinopathic diseases.
Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) correspond to a group of necrotizing vasculitides of medium (0.2 to 2.0 mm in diameter) and small blood vessels (arterioles, capillaries, postcapillary venules). Clinically, it is characterized by multisystem involvement, with upper and lower respiratory tract and renal damage standing out for their frequency. The least frequent manifestations are cutaneous, with digital ischemia and gangrene occurring in less than 1% of cases.
The diagnosis is based on a detailed clinical history and physical examination in addition to complementary studies including a complete metabolic panel, muscle enzymes, viral panel, thyroid profile and a rheumatologic panel to assess secondary causes of Raynaud's phenomenon.
Calcium antagonists are considered the first-line treatment in both etiologies, and phosphodiesterase-5 inhibitors are another alternative.
This article presents a case of a patient with Raynaud's phenomenon as an initial clinical manifestation and later presentation of C-ANCA vasculitis.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. Vulasala, S. S., Ahmed, S., Onteddu, N. K., Mannem, M., & Mukkera, S. (2021). Raynaud's Secondary to Granulomatosis With Polyangiitis. Cureus, 13(8), e17551. https://doi.org/10.7759/cureus.17551
II. Fardoun, M. M., Nassif, J., Issa, K., Baydoun, E., & Eid, A. H. (2016). Raynaud's Phenomenon: A Brief Review of the Underlying Mechanisms. Frontiers in pharmacology, 7, 438. https://doi.org/10.3389/fphar.2016.00438
III. Choi, E., & Henkin, S. (2021). Raynaud's phenomenon and related vasospastic disorders. Vascular medicine (London, England), 26(1), 56–70. https://doi.org/10.1177/1358863X20983455
IV. Temprano KK. (2016) A Review of Raynaud's Disease. Missouri Medicine. Mar-Apr;113(2):123-6. PMID: 27311222; PMCID: PMC6139949.
V. Haque, A., & Hughes, M. (2020). Raynaud's phenomenon. Clinical medicine (London, England), 20(6), 580–587. https://doi.org/10.7861/clinmed.2020-0754
VI. Micheletti, R. G., Chiesa Fuxench, Z., Craven, A., Watts, R. A., Luqmani, R. A., & Merkel, P. A. (2020). Cutaneous manifestations
VII. of anti‐neutrophil cytoplasmic antibody‐associated vasculitis. Arthritis & Rheumatology. (Hoboken, N.J.), 72(10), 1741–1747. https://doi.org/10.1002/art.41310
VIII. Pauling, J. D., Hughes, M., & Pope, J. E. (2019). Raynaud's phenomenon-an update on diagnosis, classification and management. Clinical rheumatology, 38(12), 3317–3330. https://doi.org/10.1007/s10067-019-04745-5
IX. Souza, E. J. do R. e, & Kayser, C. (2015). Nailfold capillaroscopy: relevance to the practice of rheumatology. Revista Brasileira de Reumatología (English Edition), 55(3), 264–271. https://doi.org/10.1016/j.rbre.2014.09.005
X. Shapiro, S. C., & Wigley, F. M. (2017). Treating Raynaud phenomenon: Beyond staying warm. Cleveland Clinic journal of medicine, 84(10), 797–804. https://doi.org/10.3949/ccjm.84a.17025
XI. Shenoy PD, Kumar S, Jha LK, Choudhary SK, Singh U, Misra R, Agarwal V. (2010). Efficacy of tadalafil in secondary Raynaud’s phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial, Rheumatology, Volume 49 Issue 12. 2420–2428, https://doi.org/10.1093/rheumatology/keq291
XII. Lutalo, P. M., & D'Cruz, D. P. (2014). Diagnosis and classification of granulomatosis with polyangiitis (aka Wegener's granulomatosis). Journal of autoimmunity, 48-49, 94–98. https://doi.org/10.1016/j.jaut.2014.01.028
XIII. Allard-Chamard, H., & Liang, P. (2019). Antineutrophil Cytoplasmic Antibodies Testing and Interpretation. Clinics in Laboratory Medicine, 39(4), 539–552. https://doi.org/10.1016/j.cll.2019.07.003
XIV. Lau, R. A., Bains, R., Suraweera, D., Ma, J., Heinze, E. R., Wong, A. L., & Clements, P. J. (2017). A Rare Case of Digital Ischemia and Gangrene in ANCA-Associated Vasculitis with Review of the Literature. Case reports in rheumatology, 2017, 2421760. https://doi.org/10.1155/2017/2421760
XV. Kubaisi, B., Abu Samra, K., & Foster, C. S. (2016). Granulomatosis with polyangiitis (Wegener's disease): An updated review of ocular disease manifestations. Intractable & rare diseases research, 5(2), 61–69. https://doi.org/10.5582/irdr.2016.01014.
XVI. Kitching, A. R., Anders, H. J., Basu, N., Brouwer, E., Gordon, J., Jayne, D. R., Kullman, J., Lyons, P. A., Merkel, P. A., Savage, C. O. S., Specks, U., & Kain, R. (2020). ANCA-associated vasculitis. Nature reviews. Disease primers, 6(1), 71. https://doi.org/10.1038/s41572-020-0204-y
XVII. Ladrón de Guevara, David, Cerda, Felipe, Ángela Carreño, María, Piottante, Antonio, & Bitar, Patricia. (2019). Actualización en el estudio de Granulomatosis con poliangeitis (Granulomatosis de Wegener). Revista chilena de radiología, 25(1), 26-34. https://dx.doi.org/10.4067/S0717-93082019000100026
XVIII. Almaani, S., Fussner, L. A., Brodsky, S., Meara, A. S., & Jayne, D. (2021). ANCA-Associated Vasculitis: An Update. Journal of clinical medicine, 10(7), 1446. https://doi.org/10.3390/jcm10071446
XIX. Lakhani, D. A., Balar, A. B., Adelanwa, A., Gross, A., Mohamed, R., Smith, K. T., & Kim, C. (2021). Granulomatosis with polyangiitis: A case report and brief review of literature. Radiology case reports, 16(11), 3445–3450. https://doi.org/10.1016/j.radcr.2021.08.028.
XX. Devgire, V., & Hughes, M. (2019). Raynaud's phenomenon. British journal of hospital medicine (London, England : 2005), 80(11), 658–664. https://doi.org/10.12968/hmed.2019.80.11.658
XXI. Ross, C., Makhzoum, J. P., & Pagnoux, C. (2022). Updates in ANCA-associated vasculitis. European journal of rheumatology, 9(3), 153–166. https://doi.org/10.5152/eujrheum.2022.20248.